Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Vaccine crawled time : 23:00 save search
Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine
Published: 2023-12-06 (Crawled : 23:00) - prnewswire.com
ANIX | $3.01 52K
|
Health Technology
|
| O: 2.29%
H: 5.63%
C: -10.45%
vaccine breast positive cancer study
Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer’s Vaccine at CTAD
Published: 2023-10-24 (Crawled : 23:00) - globenewswire.com
GRFS | $6.435 2.14% 1.3M
|
Health Technology
|
| O: -4.21%
H: 1.1%
C: 0.26%
biotech vaccine alzheimer’s positive results study phase 2
Genevant Sciences LNP Technology Used in samRNA Covid-19 Vaccine Candidate Behind Gritstone bio’s BARDA Award
Published: 2023-10-12 (Crawled : 23:00) - biospace.com/
GRTS | $0.7411 -0.59% 1.6M
|
Health Technology
|
| O: 0.0%
H: 1.19%
C: -4.31%
covid-19 award candidate vaccine sciences technology
Global Influenza Vaccine Market Research Report 2023-2028: Shift in Trends towards mRNA-based Flu Vaccine Gaining Momentum
Published: 2023-10-05 (Crawled : 23:00) - prnewswire.com
GLAXF | News | $20.305 630
|
Health Technology
|
| O: 0.5%
H: 0.0%
C: 0.0%
AZNCF | News | $138.73 3.7K
|
Health Technology
|
| O: -0.48%
H: 1.63%
C: -0.57%
GSK | News | $41.13 1.33% 1.1M
|
Health Technology
|
| O: 0.94%
H: 0.82%
C: 0.41%
SNY | News | $47.85 1.49% 920K
|
Health Technology
|
| O: -0.19%
H: 0.0%
C: 0.0%
AZN | News | $70.87 1.06% 3M
|
Health Technology
|
| O: 0.24%
H: 0.78%
C: 0.57%
report vaccine momentum influenza research global trends market
Ligand’s Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials
Published: 2023-07-27 (Crawled : 23:00) - biospace.com/
LGND | $70.655 3.1% 61K
|
Health Technology
|
| O: 0.68%
H: 0.63%
C: -1.09%
pneumococcal vaccine merck trials
MODERNA INITIATES ROLLING SUBMISSION TO HEALTH CANADA FOR UPDATED COVID-19 VACCINE
Published: 2023-06-29 (Crawled : 23:00) - biospace.com/
MRNA | News S | $107.33 2.75% 1.2M
|
Health Technology
|
| O: -0.41%
H: 0.39%
C: -0.32%
covid-19 vaccine health canada submission
SK bioscience-Sanofi Announce Positive Results from Phase II Study of 21-Valent Pneumococcal Conjugate Vaccine Candidate
Published: 2023-06-29 (Crawled : 23:00) - prnewswire.com
SNY | News | $47.85 1.49% 920K
|
Health Technology
|
| O: 0.94%
H: 0.0%
C: 0.0%
candidate pneumococcal vaccine positive results study
US FDA Approves GSK’s AREXVY, the World’s First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults
Published: 2023-05-03 (Crawled : 23:00) - biospace.com/
GSK | News | $41.13 1.33% 1.1M
|
Health Technology
|
| O: 1.24%
H: 1.14%
C: 0.11%
AGEN A | $6.93 20.1% 710K
|
Health Technology
|
| O: 1.42%
H: 6.99%
C: 4.2%
fda vaccine respiratory virus
Anixa Biosciences and Cleveland Clinic Present Positive Data for Phase 1 Study of Breast Cancer Vaccine
Published: 2023-04-17 (Crawled : 23:00) - biospace.com/
ANIX | $3.01 52K
|
Health Technology
|
| O: 1.84%
H: 6.09%
C: -25.82%
vaccine breast positive cancer study
Tonix Pharmaceuticals Presents Data from its Vaccine Development Program at the World Vaccine Congress
Published: 2023-04-06 (Crawled : 23:00) - globenewswire.com
TNXP | $0.1568 0.9% 900K
|
Health Technology
| Email alert
Add to watchlist
vaccine pharmaceuticals program
Emergent BioSolutions Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines
Published: 2022-11-01 (Crawled : 23:00) - biospace.com/
EBS | News | $2.295 6.25% 490K
|
Health Technology
|
| O: 1.87%
H: 1.46%
C: -1.55%
candidate vaccine study chikungunya
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of GRANITE, Individualized Neoantigen Vaccine for Solid Tumors
Published: 2022-08-15 (Crawled : 23:00) - biospace.com/
GRTS | $0.7411 -0.59% 1.6M
|
Health Technology
|
| O: 0.0%
H: 3.41%
C: -0.73%
vaccine study phase 1
Patients with Lupus Benefit from COVID-19 Vaccine Booster
Published: 2022-07-12 (Crawled : 23:00) - prnewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -0.1%
H: 0.0%
C: -2.06%
JNJ | News | $150.09 0.65% 3.9M
|
Health Technology
|
| O: -1.37%
H: 0.38%
C: -0.13%
SNY | News | $47.85 1.49% 920K
|
Health Technology
|
| O: -1.38%
H: 0.0%
C: 0.0%
covid-19 vaccine lupus
Novavax and Serum Institute of India Announce First Emergency Use Authorization of Novavax' COVID-19 Vaccine in Adolescents ≥12 to & 18 in India
Published: 2022-03-22 (Crawled : 23:00) - biospace.com/
NVAX | $4.22 3.69% 2M
|
Health Technology
|
| O: -0.64%
H: 9.36%
C: 7.35%
covid-19 authorization india vaccine emergency use authorization
Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster Dose of their COVID-19 Vaccine for Older Adults
Published: 2022-03-15 (Crawled : 23:00) - globenewswire.com
PFE | News A | $26.24 -0.08% 11M
|
Health Technology
|
| O: 0.56%
H: 0.0%
C: 0.0%
SNY | News | $47.85 1.49% 920K
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: 0.0%
BNTX | News | $88.24 0.26% 180K
|
Health Technology
|
| O: 1.63%
H: 11.55%
C: 11.21%
covid-19 covid authorization vaccine tiona merge order emergency use authorization
Vaccinex, Inc. Announces Upcoming Presentation at the 2022 American Association for Cancer Research Meeting Updating the Phase 1b Segment of the KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck Cancer
Published: 2022-03-09 (Crawled : 23:00) - globenewswire.com
VCNX | $4.94 6.4K
|
Health Technology
|
| O: 1.83%
H: 18.92%
C: 17.12%
america ema phase 1b research presentation pepinemab phase 1 keytruda dating cancer head and neck vaccine phase 2b
Amidst Record Vaccination Numbers, Puerto Rico Drops Nearly All COVID Restrictions
Published: 2022-03-07 (Crawled : 23:00) - prnewswire.com
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
|
| O: -2.18%
H: 0.0%
C: 0.0%
covid drop vaccine
Novavax Announces Extended Durability of Protection Against Infection and Disease in United Kingdom COVID-19 Vaccine Phase 3 Clinical Trial
Published: 2022-02-28 (Crawled : 23:00) - biospace.com/
NVAX | $4.22 3.69% 2M
|
Health Technology
|
| O: -0.81%
H: 3.12%
C: 2.96%
covid-19 trial covid disease vaccine infection phase 3 infections
US-Authorized COVID-19 Vaccines Generate More Than $30 Billion in 2021
Published: 2022-02-24 (Crawled : 23:00) - biospace.com/
JNJ | News | $150.09 0.65% 3.9M
|
Health Technology
|
| O: -1.05%
H: 0.0%
C: 0.0%
covid-19 covid authorized vaccine
Medicago’s Plant-Based Vaccine Bolstered by GSK Adjuvant Approved in Canada
Published: 2022-02-24 (Crawled : 23:00) - biospace.com/
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 0.78%
H: 0.0%
C: 0.0%
JNJ | News | $150.09 0.65% 3.9M
|
Health Technology
|
| O: -1.05%
H: 0.0%
C: 0.0%
SNY | News | $47.85 1.49% 920K
|
Health Technology
|
| O: -4.06%
H: 0.0%
C: 0.0%
vaccine
Gainers vs Losers
| 87% | 13% |
Top 10 Gainers
MTTR | News M | $4.64 166.67% 18M
|
AGBA | $2.61 108.8% 41M
|
Finance
CZOO | $9.32 86.77% 18M
|
EDBL | News | $6.7 78.19% 1.7M
|
OPRT | News | $3.37 49.78% 8.9M
|
Finance
MTC | $2.14 37.18% 4.9M
|
Technology Services
VNRX | $0.8 33.33% 2.9M
|
Health Technology
MLEC | $1.79 27.86% 2.6M
|
n/a
PALI | $6.29 27.59% 22M
|
Manufacturing
MCRB | $0.7902 26.51% 6.9M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.